Sarepta Therapeutics | SRPT - 资产



金融业
股票价格
USD
资产
USD 3.18B
现金及等价物
USD 464.45M
销售成本
USD 109.46M
流动资产
USD 2.31B
流动负债
USD 499.16M
债务
USD 1.04B
EBIT
USD 358.43M
EBITDA
USD -252.2M
员工
1.37K
EPS每股收益
USD 3.16
股本和储备
USD 1.51B
销售毛利
USD 621.34M
债务利息支出
USD 20.84M
利息收入
USD 8.74M
贷款资金
USD 838.16M
市值
USD 1.58B
净收入
USD 330.96M
营业费用
USD 372.37M
营业利润
USD 358.43M
普通股股本
USD 105.57M
PE价格收益
27.27
税前利润
USD 343.17M
销售收入
USD 730.8M
销售和管理费用
USD 54.03M
股票
USD 1B
贸易债权人
USD 70.38M
应收帐款人
USD 547.91M


资产 更改 日
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Capricor Therapeutics USD 326.28M 29.66M 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Incyte USD 7.34B 381.14M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novavax USD 1.04B 133.35M 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Tectonic Therapeutic USD 246.58M 14.46M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03